Core Viewpoint - MicroPort Robotics-B (02252) has achieved a significant milestone with over 200 global commercial orders for its TiMeye® laparoscopic surgical robot, indicating widespread recognition of its clinical value and safety [1] Group 1: Company Performance - As of the announcement date, the company has completed nearly 130 installations of the TiMeye system, demonstrating its growing market presence [1] - The stock opened over 3% higher and is currently trading at 26.8 HKD with a transaction volume of 2.987 million HKD [1] Group 2: Product Development - The TiMeye system is the first remote surgical robot approved for commercial use, with approvals in nearly 10 countries including China, India, and Brazil, covering regions with nearly half of the global population [1] - The system has successfully completed nearly 800 remote surgeries across over 20 countries, maintaining a 100% success rate [1] Group 3: Market Recognition - The increase in commercial orders and installations reflects the system's systematic certification of safety, stability, and reliability, as recognized by surgeons from various countries and medical backgrounds [1]